Abstract: “Chronic hepatitis B prevention and treatment guidelines (2015 edition)” pointed out that if
hepatitis B virus load ＞ 2 × 10 6 IU/ml in late pregnancy, tenofovir, telbivudine or lamivudinecan should
be administered at 24～28 weeks of pregnancy in order to improve the success rate of the prevention of
mother-to-child transmission (PMTCT). This paper reviews the necessity, effectiveness and safety of antiviral
treatment in late pregnancy, predictors of ALT elevations, timing of deactivate antiviral drugs and ways to
furtherly improve the success rate of PMTCT.